Biology of Blood and Marrow Transplantation This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis
Richter transformation (RT) of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma has an estimated median OS of only 8-12 mo. Tisagenlecleucel CAR-T cell therapy is approved for treatment of r/r LBCL after ≥2 lines of prior therapy. Here, we describe the efficacy and safety of tisagenlecleucel in patients (pts) with RT in a real-world setting with a median follow-up (infusion to data cutoff) of 31 mo. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Mazyar Shadman, Matthew J. Frigault, Stephen Ronan Foley, Brian T. Hill, Grant Schofield, Caron A. Jacobson, Samantha Jaglowski, Frederick L. Locke, Daniel J. Landsburg, Ron Ram, Peter A. Riedell, Gunjan L. Shah, Leslie Popplewell, Ranjan Tiwari, Stephen Tags: 245 Source Type: research

Outcomes of Patients Underrepresented in Pivotal Trials of Anti-CD19 CAR-T Cell Therapy
Three commercial anti-CD19 chimeric antigen receptor modified T-cell therapies (CAR-T) were approved for the treatment of chemo-refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) based on results from pivotal registration trials that had strict inclusion and exclusion criteria. Additionally, despite enrollment across multiple large centers, underrepresented minorities (URMs) accounted for a small portion of the trial participants (e.g., only 11% enrolled to ZUMA1 were non-White). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Daniel Goyco Vera, Jonathan Lockhart, George Carrum, Rammurti T. Kamble, LaQuisa Chimere Hill, Dr. Carlos A. Ramos, Sai Ravi Pingali, Helen E. Heslop, Premal D. Lulla Tags: 246 Source Type: research

Earlier Steroid Use Does Not Decrease the Severity or Duration of Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Large B-Cell Lymphoma (LBCL) Who Received Axicabtagene Ciloleucel (axi-cel).
Axi-cel continues to show durable responses in a subset of patients with LBCL (Neelapu et al. 2023). Management of two common axi-cel toxicities, CRS and ICANS, includes the use of steroids (Santomasso et al. 2021), although the optimal dose and timing remains unknown. In this single-center retrospective study we investigated the importance of steroid treatment timing by comparing patients treated before and after the implementation of an early steroid treatment standard operating procedure (SOP) for low grade CRS and ICANS at the University of Rochester. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Samuel Weeks, Myla Strawderman, Kara Kubli, Joseph DiTursi, Patrick M. Reagan Tags: 247 Source Type: research

Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)
Axi-cel is a CD19-directed autologous CAR T-cell therapy approved for the treatment of relapsed/refractory lymphomas. In a 5-year follow-up of ZUMA-1 (Neelapu et al, 2023) 58% of patients (pts) achieved CR, among whom 63% achieved CR by the week-4 assessment. Here, we evaluated the dynamics of achieving CR and its impact on survival in pts with R/R LBCL treated with axi-cel in the real world.Pts who received axi-cel for R/R LBCL in the US between 2017 –2020 after ≥ 2 lines of prior therapy and enrolled in the CIBMTR database were analyzed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Armin Ghobadi, Theodora Anagnostou, Jacques Azzi, Mehdi Hamadani, Brent Logan, Michael T Hemmer, Sairah Ahmed, Sushma Bharadwaj, Alex F. Herrera, Caron A. Jacobson, Frederick L. Locke, Hai-Lin Wang, Myrna Nahas, Timothy Best, Sachin Vadgama, Zhen-Huan Hu, Tags: 248 Source Type: research

Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & Toxicity
CD19 CAR-T therapy has revolutionized the management of high risk& relapsed/refractory (R/R) large B-cell lymphoma (LBCL) but remains limited by significant toxicities. In the absence of head-to-head randomized clinical trial data, we evaluated the impact of CAR-T product type on the outcomes of LBCL patients (pts) receiving liso-cel or axi-cel per standard of care.All LBCL pts treated at our center with liso-cel or axi-cel outside of a clinical trial between 1/2018& 6/2023 were included. Best response was determined within 3 months of CAR-T infusion by PET-CT imaging (Lugano 2014 criteria). (Source: Biology of Blood and M...
Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Andrew J. Portuguese, Aya Albittar, Jennifer J. Huang, Emily C. Liang, Natalie Wuliji, Mahnoosh Taheri, Alexandre V Hirayama, Erik L. Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude Tags: 249 Source Type: research